Low molecular weight TK inhibitors (TKIs) of the EGFR, such as gefitinib and erlotinib, have been proven particularly effective as first-line treatment in NSCLC patients, whose tumors harbor activating mutations in the EGFR TK domain. This evidence concerns the gene TKT and non-small cell lung carcinoma.